NXTCL — NextCell Pharma AB Balance Sheet
0.000.00%
Last trade - 00:00
- SEK43.15m
- SEK12.75m
- SEK10.11m
2019 August 31st | 2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 20.1 | 22 | 139 | 97.1 | 50 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.2 | 1.27 | 1.7 | 2.71 | 3.58 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 23.2 | 26 | 146 | 107 | 67.3 |
Net Property, Plant And Equipment | 2.48 | 2.61 | 2.9 | 2.34 | 1.96 |
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 26.7 | 29.8 | 156 | 125 | 88.8 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.82 | 2.17 | 3.96 | 6.93 | 10.1 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 3.76 | 3.56 | 5.53 | 9.12 | 13.1 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 23 | 26.2 | 150 | 116 | 75.7 |
Total Liabilities & Shareholders' Equity | 26.7 | 29.8 | 156 | 125 | 88.8 |
Total Common Shares Outstanding |